KLH45 is a potent and selective DDHD2 inhibitor (IC50 = 1.3 nM); it completely inactivates DDHD2 (>95% inhibition) in Neuro2A cells at 25 nM for 4 h with no cross-reactivity against over 40 other serine hydrolases except ABHD6; it increases lipid droplet (LD) formation in fatty acid-supplemented, DDHD2-expressing cells; in vivo, KLH45 (20 mg/kg, administered every 12 h for 4 days) significantly elevates several triacylglycerols (TAGs) that accumulate in the brains of DDHD2−/− mice.